RACE ONCOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 AUD | +7.22% |
|
+15.57% | +67.86% |
| Mar. 26 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
| Mar. 18 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 234M 155M |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -7.26M | Net income 2025 * | -13M -8.58M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 9.3M 6.14M | Net cash position 2025 * | 33.5M 22.1M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-19.6
x | P/E ratio 2025 * |
-17.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +7.22% | ||
| 1 week | +15.57% | ||
| Current month | +12.35% | ||
| 1 month | -8.44% | ||
| 3 months | +93.15% | ||
| 6 months | +51.61% | ||
| Current year | +67.86% |
1 week
1.16
1.41
1 month
1.141.52
Current year
0.641.81
1 year
0.641.82
3 years
0.644.04
5 years
0.054.23
10 years
0.054.23
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tillett
CEO | Chief Executive Officer | - | Nov. 21 |
| Chief Tech/Sci/R&D Officer | - | 23-06-30 | |
Tim Hammond
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Smith
BRD | Director/Board Member | 61 | 23-06-28 |
Borje Andersson
PRN | Corporate Officer/Principal | - | 20-01-31 |
Phillip Lynch
BRD | Director/Board Member | - | 20-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.41 | +7.22% | 182,906 |
| 24-05-09 | 1.315 | +4.37% | 115,666 |
| 24-05-08 | 1.26 | +3.28% | 97,246 |
| 24-05-07 | 1.22 | +2.52% | 66,453 |
| 24-05-06 | 1.19 | -2.46% | 21,196 |
Delayed Quote Australian S.E., May 10, 2024 at 02:10 am EDT
More quotes
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Calendar
2024-08-22
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +67.86% | 155M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RAC Stock